

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Garella Rahul</u> (Last) (First) (Middle) C/O ENDO INTERNATIONAL PLC FIRST FL, MINERVA HOUSE, SIMMONSCOURT RD (Street) BALLSBRIDGE, L2 DUBLIN (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Endo International plc [ENDP]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) EVP, Intl Pharmaceuticals
	3. Date of Earliest Transaction (Month/Day/Year) 03/29/2020	
4. If Amendment, Date of Original Filed (Month/Day/Year)		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Ordinary Shares	03/29/2020 ⁽¹⁾		F		4,214 ⁽²⁾	D	\$3.47 ⁽³⁾	40,470	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V		Date Exercisable	Expiration Date					

Explanation of Responses:

- Thirty-three and one-third percent (33 1/3%) of Mr. Garella's March 29, 2019 grant of restricted stock units (RSUs) vested on March 29, 2020.
- These shares represent stock withheld by Endo International plc to satisfy Mr. Garella's tax withholding obligations on shares acquired upon vesting of RSUs.
- Represents the vesting price which is the closing share price on March 27, 2020, the last trading day prior to vesting.

Remarks:

/s/ Yoon Ah Oh, by power of attorney 03/31/2020

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

LIMITED POWER OF ATTORNEY FOR
SECTION 16 REPORTING OBLIGATIONS

Know all by these present that the undersigned hereby makes, constitutes and appoints Matthew J. Maletta, Yoon Ah Oh, Carrie A. Nichol, Ju:
(1) prepare, execute, acknowledge, deliver and file Forms 3, 4, and 5 (including any amendments thereto) with respect to the securities of I
(2) seek or obtain, as the undersigned's representative and on the undersigned's behalf, information on transactions in the Company's secur:
(3) perform any and all other acts which in the discretion of such attorney-in-fact are necessary or desirable for and on behalf of the und
The undersigned acknowledges that:

- (1) this Power of Attorney authorizes, but does not require, such attorney-in-fact to act in their discretion on information provided to su
- (2) any documents prepared and/or executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney will be
- (3) neither the Company nor such attorney-in-fact assumes (i) any liability for the undersigned's responsibility to comply with the require
- (4) this Power of Attorney does not relieve the undersigned from responsibility for compliance with the undersigned's obligations under the

The undersigned hereby gives and grants the foregoing attorney-in-fact full power and authority to do and perform all and every act and thing v

This Power of Attorney shall remain in full force and effect with respect to each undersigned until revoked by such undersigned in a signe

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 1 day of August 2019.

SIGNATURE

TITLE

/S/ RAHUL GARELLA Executive Vice President, International Pharmaceuticals
NAME: Rahul Garella

STATE OF Dublin, Ireland:
COUNTY OF Dublin, Ireland:

On this 1 day of August 2019, the above-named individual personally appeared before me, and acknowledged that he executed the foregoing instrum
IN WITNESS WHEREOF, I have hereunto set my hand and official seal.

/S/ JAMES JONES
Notary Public